Phase 1/​2a Study of SQ3370 in Patients With Advanced Solid Tumors

NCT 04106492

Brief Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.

Intervention / Treatment 

  • Drug: SQ3370

Inclusion Criteria

  1. Diagnosis of advanced soft tissue sarcoma or other solid tumors
  2. Adequate hematologic, hepatic, renal, and coagulation function
  3. ECOG performance status score 0-1
  4. Tumor is the type where published clinical data would suggest that anthracyclines have cytotoxic activity
  5. Injectable tumor present

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.